Kidney tubule iron loading in experimental focal segmental glomerulosclerosis

Kidney iron deposition may play a role in the progression of tubulointerstitial injury during chronic kidney disease. Here, we studied the molecular mechanisms of kidney iron loading in experimental focal segmental glomerulosclerosis (FSGS) and investigated the effect of iron-reducing interventions...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2022-01, Vol.12 (1), p.1199-1199, Article 1199
Main Authors: van Swelm, Rachel P. L., Beurskens, Sanne, Dijkman, Henry, Wiegerinck, Erwin T. G., Roelofs, Rian, Thévenod, Frank, van der Vlag, Johan, Wetzels, Jack F. M., Swinkels, Dorine W., Smeets, Bart
Format: Article
Language:English
Subjects:
692/4022
692/4022/1585
692/699/1585/104
Angiotensin-Converting Enzyme Inhibitors - therapeutic use
Animals
Blood pressure
Captopril - therapeutic use
Chelation
Chelation therapy
Cytokines
Deferoxamine
Deferoxamine - therapeutic use
Diabetes
Diet
Disease Models, Animal
Distal tubules
Female
Fibrosis
Gene expression
Glomerulosclerosis, Focal Segmental - diet therapy
Glomerulosclerosis, Focal Segmental - drug therapy
Glomerulosclerosis, Focal Segmental - metabolism
Heme
Heme oxygenase (decyclizing)
Humanities and Social Sciences
Injection
Interleukin 6
Iron
Iron - metabolism
Iron deficiency
Kidney diseases
Kidney Tubules, Distal - metabolism
Kidneys
Laboratories
Life sciences
Male
Mice
Molecular modelling
Monoclonal antibodies
multidisciplinary
Nephrology
Nutrient deficiency
Oxidative stress
Oxygenase
Proteins
Proteinuria
Receptors, Cell Surface - metabolism
Science
Science (multidisciplinary)
Siderophores - therapeutic use
Urine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Kidney iron deposition may play a role in the progression of tubulointerstitial injury during chronic kidney disease. Here, we studied the molecular mechanisms of kidney iron loading in experimental focal segmental glomerulosclerosis (FSGS) and investigated the effect of iron-reducing interventions on disease progression. Thy-1.1 mice were injected with anti-Thy-1.1 monoclonal antibody (mAb) to induce proteinuria. Urine, blood and tissue were collected at day (D)1, D5, D8, D15 and D22 after mAb injection. Thy-1.1 mice were subjected to captopril (CA), iron-deficient (ID) diet or iron chelation (deferoxamine; DFO). MAb injection resulted in significant albuminuria at all time points (p 
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-022-05261-4